Literature DB >> 32249718

Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.

Lazaros Belbasis1, Vanesa Bellou1, Evangelos Evangelou2, Ioanna Tzoulaki2.   

Abstract

Multiple sclerosis (MS) is a chronic demyelinating disease that is associated with permanent disability and low quality of life. Development of MS is attributed to a combination of genetic and environmental factors. Genome-wide association studies revealed more than 200 variants that are associated with risk of MS. An umbrella review showed that smoking, history of infectious mononucleosis, and anti-Epstein-Barr virus nuclear antigen (anti-EBNA) immunoglobulin G (IgG) seropositivity are credible risk factors of MS. In the present narrative review, we updated our published umbrella review, showing that body mass index in childhood and adolescence and anti-viral capsid antigen (anti-VCA) IgG seropositivity are additional credible risk factors of MS. In addition, we discuss the findings from Mendelian randomization studies, which present evidence for a potential causal role of serum vitamin D and adulthood body mass index on risk of MS. Finally, we discuss the potential limitations of meta-analyses, umbrella reviews, and Mendelian randomization studies in the search for risk factors of MS.

Entities:  

Keywords:  Biomarkers; Mendelian randomization; environmental factors; meta-analysis; multiple sclerosis; risk factors; umbrella review

Mesh:

Substances:

Year:  2019        PMID: 32249718     DOI: 10.1177/1352458519872664

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review.

Authors:  Elena Dragioti; Joaquim Radua; Marco Solmi; Celso Arango; Dominic Oliver; Samuele Cortese; Peter B Jones; Jae Il Shin; Christoph U Correll; Paolo Fusar-Poli
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

2.  Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.

Authors:  Thomas Lehnert; Christian Röver; Sascha Köpke; Jordi Rio; Declan Chard; Andrea V Fittipaldo; Tim Friede; Christoph Heesen; Anne C Rahn
Journal:  Syst Rev       Date:  2022-07-01

3.  Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews.

Authors:  Alexios-Fotios A Mentis; Efthimios Dardiotis; Vasiliki Efthymiou; George P Chrousos
Journal:  BMC Med       Date:  2021-01-13       Impact factor: 8.775

Review 4.  Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis.

Authors:  Maria Pia Amato; Nicola De Stefano; Matilde Inglese; Emanuele Morena; Giovanni Ristori; Marco Salvetti; Maria Trojano
Journal:  Front Neurol       Date:  2022-03-14       Impact factor: 4.003

Review 5.  Predicting Multiple Sclerosis: Challenges and Opportunities.

Authors:  Luke Hone; Gavin Giovannoni; Ruth Dobson; Benjamin Meir Jacobs
Journal:  Front Neurol       Date:  2022-02-08       Impact factor: 4.086

6.  Description and preliminary experience with Virtual Visit Assessment (ViVA) during the COVID-19 pandemic, a structured virtual management protocol for patients with multiple sclerosis.

Authors:  Roberto Bergamaschi; Livio Tronconi; Daniele Bosone; Antonella Mastretti; Laura Jommi; Marco Andrè Bassano; Renato Turrini; Sara Benati; Marco Volpe; Jean Marie Franzini; Silvia Allodi; Giulia Mallucci
Journal:  Neurol Sci       Date:  2021-06-15       Impact factor: 3.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.